NEW YORK (GenomeWeb) – Citigroup this week initiated coverage of Cepheid with a Buy rating and a price target on its shares of $52.
NEW YORK (GenomeWeb News) – Citi Research analyst Amit Bhalla has increased his price target on Agilent Technologies' stock from $43 to $50 and has increased earnings-per-share estimates for the firm.
NEW YORK (GenomeWeb News) – Citigroup today initiated coverage of Agilent Technologies with a Buy rating and a $46 target on the company's stock.
By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Citigroup upgraded Life Technologies to Buy today following last week's contraction in the company's stock price.
Analyst Amit Bhalla said that trade-in revenue from customers who purchase the HiSeq 2000 platform would not be a "significant contributor," and trimmed total revenue estimates for the second quarter and full-year 2011.
The bank also placed a price target of $52 on Illumina's stock.
In Science this week: genetic target for urothelial bladder cancer treatment, and more.
At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.
Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.
Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.